Clay Siegall to Introduce Better Drugs and Hire More Employees

Dr. Clay Siegall is one of the most successful scientists in the world. At the moment, he serves as the chief executive officer and chairman of a biotechnology company known as Seattle Genetics. As the president and chief executive director of the respected organization, Clay Siegall has introduced several changes.

Clay Siegall established the biotechnology company in the year 1998, and he has done very well to ensure that it is one of the best in the industry. As the chairman of the board of directors and president of the company, Clay is in charge of the capital raising activities in the enterprise. He also ensures that clients get the best cancer treatment drugs. Before starting the successful biotechnology company, Clay was serving at the well-known Bristol-Myers Pharmaceutical Research Institute. The scientist has also worked for the National Cancer Institute.

Last year, Clay Siegall was appointed to serve as the external director for a company known as Mirna Therapeutics. The scientist is believed to have acquired this prestigious position due to his expertise in biotechnology and cancer research. Mirna Therapeutics says that they thought Clay Siegall is the right person for the job. According to them, Clay will bring the changes needed in the industry. The scientist went for his education at the prestigious University of Maryland where he acquired his BS in Zoology. Later on, he got a Ph.D. in Genetics from the popular George Washington University.

In a recent post, Clay Siegall has announced that he has successfully managed to raise capital for the organization. According to him, the money was going to be used for cancer research and treatment. The company will be introducing more cancer drugs in the market so that individuals living with cancer can be saved. Clay Siegall plans to increase the number of his employees too in the recent future. These professionals will have to be highly qualified and experienced so that they can get a position in the company. One of the cancer therapies from the biotechnology company, known as ADCETRIS has been doing well in the international market, and it is used in over sixty nations.